Amgen and AstraZeneca unveiled their first, direct-to-consumer U.S. advertising campaign in severe asthma called “Be You.” Launching ahead of Asthma & Allergy Awareness Month in May, the “Be You” campaign leverages visually distinct animated characters who do not let their disease define them. The campaign aims to raise awareness about a new severe asthma medicine called TEZSPIRE (tezepelumab-ekko).
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 InflammationApprovals, Asthma, EMA, European Commission, Expanded Approval, Marketing Authorization Application (MAA), Monoclonal Antibodies, Pediatric Asthma, Regeneron Pharmaceuticals, Sanofi, Severe Asthma, Severe Pediatric Asthma, Therapeutics
Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for children Data reinforce well-established safety profile […]
The U.S. Food and Drug Administration approved AstraZeneca and Amgen’s drug Tezspire to treat severe asthma for those aged 12 years and older, the companies said on December 17.
Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma.
AstraZeneca and Amgen’s experimental drug tezepelumab reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.
AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.
The European Commission approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide, who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment.
Nearly two weeks after the U.S. Food and Drug Administration approved Sanofi and Regeneron’s Dupixent as an add-on maintenance therapy for moderate to severe asthma, the France-based company reported a surge in sales for the medication in the third-quarter 2018 report.
AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.